



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/19, 39/00		A1	(11) International Publication Number: WO 97/49421 (43) International Publication Date: 31 December 1997 (31.12.97)
(21) International Application Number: PCT/US97/10540		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB; BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 18 June 1997 (18.06.97)		(30) Priority Data: 08/671,251 27 June 1996 (27.06.96) US	
(71) Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA [US/US]; Morrill Hall, 100 Church Street S.E., Minneapolis, MN 55455 (US).		(72) Inventors: LOW, Walter, C.; 19845 Sweet Water Curve, Shorewood, MN 55331 (US). WALLENFRIEDMAN, Margaret, A.; 6805 Limerick Lane, Edina, MN 55439 (US).	
(74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).		Published <i>With international search report.</i>	

(54) Title: GM-CSF ADMINISTRATION FOR THE TREATMENT AND PREVENTION OF RECURRENCE OF BRAIN TUMORS

(57) Abstract

A method for inhibiting the growth of brain tumors comprising peripheral administration of GM-CSF in combination with brain tumor antigen.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	CN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GM-CSF ADMINISTRATION FOR THE TREATMENT AND PREVENTION OF RECURRENCE OF BRAIN TUMORS

Field of the Invention:

5 This invention relates to a therapeutic method effective for inhibiting the growth of brain tumors and preventing their reoccurrence. Specifically, the invention demonstrates that the peripheral administration of GM-CSF in combination with brain tumor antigens effectively inhibits growth of tumor cells in the brain. After such treatment, animals are resistant to further tumor challenges.

10

Background of the Invention:

Brain tumors are a leading cause of death from neurological disease. It has been estimated that approximately 11,000 people in the United States alone die each year from primary tumors of the central nervous system. The most 15 malignant form of primary intracranial tumors is glioblastoma multiforme. The mean survival time for patients with this type of tumor in the absence of any therapy is 14 weeks with a 1-year survival rate of 3%. With surgery, radiation therapy, and chemotherapy, the survival times are not dramatically prolonged. A key problem in dealing with glioblastoma is the inability of the immune system to recognize and 20 destroy these tumor cells.

Glial derived brain tumors represent a population of tumors with the capacity to evade and ultimately inhibit the body's mechanism for tumor defense. Clinical observations of patients with glioblastoma suggest that both cell mediated and humoral immunity are suppressed. These patients display cutaneous anergy, 25 decreased numbers of T-cells and diminished responses to mitogens and antigens. Their peripheral blood lymphocytes fail to produce γ -interferon (IFN- γ), granulocyte/macrophage colony stimulating factor (GM-CSF) and tumor necrosis factor- α (TNF- α) upon stimulation *in vitro*. When stimulated, T-cells from glioma patients express abnormally low levels of p55, the subunit which confers high 30 affinity to the interleukin-2 (IL-2) receptor.

The mechanisms of glioma-induced immuno-suppression are not clear. Gliomas have a low level of MHC Class I antigen expression and minimal

tumor infiltration by lymphocytes. Sera from glioma patients suppresses normal lymphocyte function, as does culture supernatant from surgically removed glioblastomas. The "glioblastoma derived T-cell suppressor factor" (G-TSF) was isolated from such glioma supernatant.

5 GM-CSF inhibits the activity of normal T-cells and is homologous to transforming growth factor β 2 (TGF- β 2). This factor appears to be responsible for the decreased levels of p55 seen in T-cells from glioma patients.

10 Current treatment of brain tumors, glioblastoma, medulloblastoma, and others, by surgical excision, radiation or chemical therapy, have not changed mean survival over the last decade. Given glioma's ability to suppress host defenses, it is not surprising that tumor cells which survive treatment will regrow. Therefore, therapeutic methods to enhance the immune system's detection and control of tumors, and especially of gliomas are greatly needed.

15 *In vivo* immunological defense against brain tumors, e.g., glioma is limited to MHC-restricted, antigen-specific cytotoxic T-lymphocytes (CTL). There is no evidence for antibody production against glioma tissue associated antigens, and glioma cells are resistant to natural killer (NK) cells. In the normal immune system, MHC-restricted cellular cytotoxicity begins with macrophages such as microglia in the brain, and Langerhan's cells in the epidermis. These sentinel cells phagocytose
20 tumors and present digested peptide antigens on the macrophage's MHC II molecules. Stimulation by cytokines causes Langerhans' cells to migrate and differentiate into peripheral dendritic cells, thought to be the major source of immunological epitopes for T-cell activation. These antigen presenting cells (APC) then activate CD4 $^+$ helper T-cells (Th-1) in the presence of macrophage-produced IL-12.
25 Th-1 cells' T-cell receptor (TCR), to which CD4 is coupled, binds to a specific MHC II restricted antigen on the APC. Once activated, Th-1 cells release IL-2 and IFN- γ to activate antigen-specific cytotoxic CD8 $^+$ T-cells and macrophages. The activated macrophages release TNF- α to kill tumor cells. The activated CTL have CD8-coupled TCR's which interact with MHC I restricted antigens on tumor
30 surfaces. This antigen-specific recognition actuates CTL to lyse and destroy the tumor cell.

The events leading to CTL activation may be divided into tasks attributed to one of two functional groups: antigen presenting "sensor" cells and lymphocytic "effector" cells. Immunological therapies to date have primarily focused on augmenting the lymphocytic "effector" cells. Lymphocytes such as 5 tumor-infiltrated lymphocytes, (TILs) or peripheral lymphokine-activated killer cells (LAK cells) have been harvested from patients, expanded or stimulated with lymphokines *ex vivo*, and re-introduced back into the patient. The efficacy of this approach is dependent upon concurrent systemic infusion of IL-2. This 10 immunotherapy has met with some success in the treatment of melanoma and renal cell carcinoma, however, it has not been successful in treating brain tumors, especially glioma.

Brain tumors, e.g., gliomas, have very few tumor-infiltrating lymphocytes and despite the effectiveness of LAK cells *in vitro*, they do not reduce gliomas *in vivo*. Additionally, there are serious side effects of high concentrations of 15 systemic IL-2, including vascular leaks resulting in cerebral edema, making this therapy particularly undesirable.

GM-CSF has long been recognized as a proliferative factor for macrophages and granulocytes. However, its immunological potential has only recently been appreciated. Endogenous tumoricidal activity has been stimulated in 20 animals immunized with tumor cell transfected with cytokines, including IL-2 into fibrosarcoma and colon carcinoma; TNF α into plasmacytoma and sarcoma; IL-7 into plasmacytoma; IFN γ into neuroblastoma, fibrosarcoma, and sarcoma; IL-6 into lung carcinoma, and GM-CSF into colon carcinoma, melanoma, and prostate carcinoma. When compared with other cytokines, GM-CSF alone (or in 25 combination with IL-2), has been found to be the most potent stimulator of systemic antitumor immunity. Moreover, tumors transfected with the gene encoding GM-CSF evoked a long lasting immune response that was generalizable to the non-transfected cells.

The majority of work to date studying on the tumoricidal potential of 30 GM-CSF has been done by viral transfections of tumor cell lines with recombinant DNA encoding GM-CSF. While these techniques are easily performed in the

laboratory using clonal cell populations, the many practical limitations of applying these techniques clinically in the brain are clear. First, the consequences of inserting viral DNA into human brain tumors, e.g., gliomas is unknown. An estimated 23 years of retroviral mediated gene transfer has been performed in humans without 5 known side effects, although some of the viral vectors being used for gene therapy have long-term potential for causing cancer. Side effects have been described in 3 monkeys at the NIH, who developed malignant T cell lymphoma after bone marrow transplant and gene transfer with a helper virus-contaminated retrovirus. Second, a therapy is needed that can be quickly and easily administered to a large number of 10 patients. The development of custom transfections of each patient's glioma cell line with a viral vector containing GM-CSF would be labor intensive and economically impractical.

Further, in contrast to other types of cancer, the treatment of brain tumors, e.g., gliomas, presents extraordinary limitations. Peripheral delivery of 15 immunogenic agents and enhancers must activate an immune response capable of exerting its effects across the blood-brain barrier. Agents delivered to peripheral sites must produce a therapeutic effect that is effective against tumors in the brain. Such effects are not predictable from successful *in vitro* studies or from studies with peripheral tumors.

20 It would be highly desirable to develop a therapeutic method and composition for the treatment of brain tumors and particularly of gliomas, that could employ peripheral delivery techniques and could adequately and comprehensively stimulate the immune system to halt growth and inhibit recurrence of tumors in the brain.

25

Summary of the Invention:

It has now been found that the peripheral administration of GM-CSF in combination with irradiated brain tumor cells successfully stimulates the immune system. The effect crosses the blood-brain barrier, prohibits the continued growth of 30 tumors in the brain, and protects the treated animal from further tumor challenges. GM-CSF, in the absence of additional cytokines such as IL-2, when co-administered

peripherally with brain tumor antigens (e.g., apoptotic irradiated tumor cells), adequately stimulates a long lasting immune response that prevents tumor growth in the brain.

5

Brief Description of the Figures

Figure 1 is a graph showing the effects of peripheral co-administration of GM-CSF and inactivated 9L cells on the growth of 9L glioblastoma tumors in the flank of host animals.

10 Figure 2 is a graph showing a dose response effect of GM-CSF co-administered with tumor antigen on the growth of brain tumors in the flank of host animals.

Figure 3 is a graph comparing the effect of GM-CSF or tumor antigen administered alone with co-administration of both agents.

15 Figure 4 is a graph showing the effect of peripheral co-administration of GM-CSF and tumor antigen on the growth of intracerebral 9L glioblastoma tumors.

Detailed Description of the Preferred Embodiments:

GM-CSF

20 GM-CSF is a small, 144 amino acid protein having multiple sites of glycosylation, an N-terminal signal sequence, and a C-terminal receptor binding domain (Rasko and Gough In: The Cytokine Handbook, A. Thomson, et al, Academic Press, New York (1994) pages 349-369). Its three-dimensional structure is similar to that of the interleukins, although the amino acid sequences are not 25 similar.

Human, recombinant GM-CSF is commercially available from Immunex (Seattle, WA). GM-CSF is administered, preferably by continuous infusion, to peripheral, subcutaneous tissues, in an aqueous medium, e.g. PBS. Human clinical studies using GM-CSF to stimulate granulocytes and macrophages 30 after chemotherapy have demonstrated patient tolerance of up to 2100 µg/day by intravenous infusion and up to 700 µg/day by subcutaneous injection without

evidence of deleterious side effects. A useful dose range in murine studies was 0.1 ng - 10 ng/day; thus, the expected useful human clinical range of GM-CSF administered is about 200 ng - 1000 µg/day, and preferably about 1 µg - 500 µg/day. Most preferably, the expected human clinical dosage rate is in the range of about 5 µg - 40 µg/day.

GM-CSF is administered by methods known for administration of a peptide therapeutic agent. Preferably, administration is by injection, and most preferably by continuous infusion in an aqueous carrier such as phosphate buffered saline (PBS).

10

TUMOR ANTIGEN

The phrase "tumor antigen" is defined in this application, includes inactivated (e.g. irradiated), whole and lysed tumor cells, and antigenic portions thereof (e.g., membranes, peptides, etc.). The tumor antigen is derived from the 15 specific patient's tumor, e.g. from biopsy tissue or from explants of a removed tumor, or from cell culture of the patient's brain tumor cells. The patient's brain tumor cells are obtained by standard biopsy methods. Cells from excised tumor tissue can be directly used, or alternatively, cells of the excised tumor can be cultured and expanded under standard culture conditions to produce increased 20 numbers of cells for use as tumor antigen.

Tumor cells are inactivated by methods known in the field, the most common method being irradiation as described in the examples below. Other known inactivation methods include oxygen deprivation, use of plant and animal toxins, and chemotherapeutic agents. Lysed tumor cells may also be used as the tumor antigen, 25 as well as cell membranes and specific tumor cell protein antigens.

For administration, the tumor antigen is suspended in an aqueous medium, e.g., PBS. The amount of tumor antigen administered is that sufficient to induce an immune response. In rat studies, administration of five million irradiated tumor cells in 300 µl PBS was efficient in preventing tumor growth, when co- 30 administered with GM-CSF. Thus, the expected useful human dose of irradiated tumor cells for subcutaneous injection is in the range of about one million to about

50 million cells, preferably about five million to 30 million cells. Administration of other types of tumor antigens, e.g. cell membrane or purified tumor cell antigens are administered to deliver a like amount of antigen.

5 **Methods of Administering**

In the method of the invention, administration of both GM-CSF and brain tumor antigen for the treatment of brain tumors is to a peripheral site, preferably by subcutaneous injection. Preferred peripheral sites for administration include the upper arm, thigh, and trunk areas of the body. It is preferred that tumor 10 antigen is administered to the same peripheral location as GM-CSF administration.

While it is contemplated that delivery of GM-CSF and tumor antigen may be simultaneous and in a single composition, the preferred route of administration is continuous infusion of the GM-CSF (e.g., for at least about 20-30 days or more, depending upon immune response) with injection of the tumor 15 antigen, e.g., at weekly intervals, beginning on the first day of GM-CSF administration. Continuous administration of GM-CSF appears to be more effective than bolus injections.

Administration of GM-CSF is preferably continuous over the treatment period. Timing of tumor antigen administration is as needed to induce 20 immune reactivity, and can be monitored by assessing change in tumor size (e.g., by MRI), immune response (e.g., by delayed type hypersensitivity skin test), and by measuring IFN-gamma secretion by the patient's TH-1 cells in response to tumor antigen.

Preferably administration of the two active agents is "essentially 25 simultaneous", meaning the GM-CSF and tumor antigen are administered to the same peripheral location at the same treatment time to induce their synergistic effect. Most preferably, tumor antigen is administered to the same subcutaneous site where GM-CSF is being infused. Continuous, subcutaneous infusion of GM-CSF is generally accomplished by attaching a pump filled with GM-CSF to plastic tubing. 30 Both the tubing and pump are preferably placed beneath the skin. The pump is refilled by injecting a syringe filled with GM-CSF through the skin and into the

pump reservoir. Tumor antigen is preferably injected by filling a syringe with inactivated antigen, e.g., irradiated tumor cells, and injecting near the tip of the plastic tubing where GM-CSF is being pumped out beneath the skin.

Treatment with both GM-CSF and tumor antigen is preferably

5 continued until immune response is detected and/or tumor ablation is achieved.

Patient Populations

Patients suffering from all types of primary brain tumors are treated by the method of the invention. The successful peripheral co-administration of GM-

10 CSF and tumor antigen for the treatment of brain tumors is surprising, given the distant location of the tumors and the potential impedance of the blood-brain barrier.

The method of treating with GM-CSF in combination with tumor antigen is particularly useful in preventing tumor reoccurrence, for example, after tumor reduction techniques, such as surgical debulking removal, irradiation, and/or

15 chemotherapy. Co-administration of GM-CSF and tumor antigen may effectively inhibits regrowth of tumor, e.g. from residual tumor cells.

The invention is further defined by reference to the following examples which are exemplary in nature and not intended to limit the scope of the invention.

20

Example 1

GM-CSF Dose-Response Effects.

The effects of the localized administration of GM-CSF at different concentrations and in the presence of irradiated 9L cells on the growth of 9L rodent

25 glioblastoma tumors implanted into the flank of immunocompetent rats was examined. Peripheral tumors were initiated by injection of 10 million non-irradiated 9L tumor cells (obtained from Dr. Patrick Wen, Harvard University) into the left flank of Fisher 344 rats (150-200g, female, Harlan).

At the time of tumor initiation, murine GM-CSF (R&D Systems) (0,

30 0.1, 1.0, or 10 ng/day; 1 million units/20 micrograms) was infused subcutaneously into the animal's right flank using surgically implanted osmotic minipumps (Alzet,

model 2004). These minipumps were set to release GM-CSF at a rate of 0.25 μ l per hour over a period of 28 days. The method of initiating tumors at the start of treatment mimics the surgical condition, where a tumor has been debulked, but some cells remain, post operatively, to induce reoccurrence of tumors.

5 At the site of continuous GM-CSF infusion, near the tip of the plastic tubing, 5×10^6 irradiated 9L glioblastoma cells (in 300 μ l PBS) were injected subcutaneously on days 0, 3, 7, 14 and 21 after tumor implantation. The 9L cells are syngeneic to the Fischer 344 rat strain rats, and were injected to stimulate an immune response. Prior to injection, these cells were irradiated with 6000 rads of
10 ^{137}Cs . At days 3, 7, 14, and 21 after tumor implantation, animals received additional inoculations of irradiated 9L cells into the site of GM-CSF infusion. GM-CSF infusion was halted after 28 days.

15 Tumor growth was measured daily for a period of 58 days after implantation, using calipers. Tumor volume was calculated according to the equation:

$$(L \times W^2)/2,$$

where L = length (mm) and W = width (mm). Each tumor was measured daily by an observer who was blinded to the treatment groups.

20 The effects of co-administered GM-CSF and irradiated 9L cells on 9L glioblastoma tumor growth in the flank of host animals are shown in Figure 1. Tumors became measurable by 11 days after implantation for animals in all groups. Tumors continued to grow for a short time period, but then began to regress for all treated animals with GM-CSF and tumor antigen. In contrast, animals treated with saline infusions displayed progressive increases in tumor size and achieved a mean
25 tumor volume greater than 30,000 mm^3 at the end of 58 days.

Tumor growth rates from days 11 to 20 were dependent on GM-CSF concentration. At 20 days after implantation, animals treated with 10 ng/day of GM-CSF and tumor antigen, exhibited the slowest growing tumors followed by animals given 1 and 0.1 ng/day (Figure 2).

Example 2**GM-CSF and Irradiated Tumor Cells Effectively Prohibit Tumor Growth**

Since the experiments of Example 1 showed the most effective GM-5 CSF dose for 9L tumor regression was 10 ng/day, this concentration was then used to determine whether the infusion of GM-CSF alone would be sufficient to stimulate an immune response, as compared with the co-administration of GM-CSF and irradiated tumor cells. In this experiment, intraflank 9L tumors were established as described for Example 1.

10 Treated animals received either (1) infusions of GM-CSF (10 ng/day), (2) infusions of GM-CSF plus irradiated tumor cells (five million cells in PBS), (3) infusions of saline plus irradiated tumor cells, or (4) no treatment. GM-CSF delivery and irradiated cell preparation and delivery was performed as described above for Example 1. Animals receiving irradiated tumor cells were 15 inoculated during the day of tumor implantation (day 0) and at 3, 7, 14, and 21 days after the implantation of the non-irradiated tumor cells. GM-CSF delivery began on the day of tumor cell injection and followed continuously throughout the treatment protocol for 28 days.

20 Non-treated animals exhibited a rapid rate of tumor growth (Figure 3). The mean tumor volume in this group was greater than 50,000 mm³ by 37 days after tumor implantation. Animals treated with GM-CSF alone exhibited a similar rate of tumor growth. Animals treated with saline and irradiated cells displayed a somewhat slower rate of growth reaching a mean volume of approximately 30,000 mm³ by 52 days after implantation.

25 In contrast to these three groups of animals, those treated with both GM-CSF and irradiated tumor cells exhibited a complete regression of tumors. These results demonstrate that both GM-CSF and irradiated tumor cells are required for the regression of the intraflank tumor, and that the combination of these two therapies results in a synergistic effect that is not seen with either agent alone.

30 To verify that this anti-tumor response was immune-mediated rather than simply toxic to the growing tumor, the animals previously "cured" of their

tumors were re-challenged with peripheral injections of 9L glioblastoma cells. Seventy (70) days had elapsed without treatment prior to rechallenge with tumor cells. Naive controls all developed tumors within 14 days. In contrast, all animals previously treated with GM-CSF and irradiated tumor cells were resistant to 5 subsequent challenges with glioblastoma.

Example 3

Effects of GM-CSF on Intracerebral Brain Tumors.

To determine the efficacy of peripherally co-administered GM-CSF 10 and tumor antigen on the survival of rats with intracerebral brain tumors, 9L tumors were established in the brains of host animals. Fischer 344 female rats (150-200g) received intracerebral injections of one million 9L cells in PBS by stereotaxic injection into the striatum. On the same day, Alza pumps were implanted subcutaneously in each animal's flank, set to release GM-CSF at a rate of 10 ng/day. 15 Following the methods described for Example 1, irradiated 9L cells were injected into the site of GM-CSF release at the time of intracerebral tumor implantation (day 0) as well as at 3 and 7 days post implantation. Control animals had established intracerebral tumors, but received no peripheral therapy.

As shown in Figure 4, approximately 22 days after implanting the 9L 20 tumors, most of the control animals had succumbed to the brain tumors. All of the animals in this group had died by day 31. In contrast, 40% of the animals receiving the GM-CSF/irradiated cell vaccinations survived beyond 167 days and have yet to expire. Localized subcutaneous delivery of GM-CSF in combination with delivery of tumor antigen (irradiated tumor cells) initiated a systemic response which led to 25 the regression of distal intracerebral tumors.

The rodent model has been used to study immunotherapeutic approaches for the treatment of other types of cancer, e.g. melanomas and lymphomas, in immunocompetent mice or rats. Clinical trials now indicate that the rodent model for immunotherapy is very predictive of what is observed in humans. 30 The rat model provides an immune system similar to that of humans. The Fischer rat system also provides well-established syngeneic brain tumor lines


that share identical immunological cell markers with the rat's normal cells, mimicking the case of human neoplasms.


It is therefore anticipated that the above-described studies using a rodent model for GM-CSF/irradiated tumor antigen treatment of brain tumors is
5 predictive of the outcome of such treatment of human brain tumors.

WHAT IS CLAIMED IS:

1. A method for inhibiting the growth of brain tumor cells in a patient, the method comprising:
 - 5 co-administering to the patient granulocyte/macrophage colony stimulating factor with tumor antigen.
2. A method for inhibiting recurrence of brain tumors in a patient, after tumor ablation, the method comprising:
 - 10 co-administering to the patient granulocyte/macrophage colony stimulating factor with tumor antigen.
3. The method of claim 1, wherein said tumor antigen comprises inactivated tumor cells or tumor cell lysate.
 - 15
 4. The method of claim 3, wherein said tumor antigen comprises irradiated tumor cells.
 5. The method of claim 1, wherein said tumor antigen is derived from the patient's brain tumor cells.
 - 20
 6. The method of claim 1, wherein said co-administering is to a peripheral, non central nervous system site.
 - 25
 7. The method of claim 6, wherein said co-administering of granulocyte/macrophage colony stimulating factor and of tumor antigen is essentially simultaneous.
 8. The method of claim 6, wherein said granulocyte/macrophage colony stimulating factor is administered by continuous infusion.
 - 30

9. The method of claim 8, wherein said tumor antigen is administered by at least one injection.
10. The method of claim 8, wherein said granulocyte/macrophage colony stimulating factor and tumor antigen are co-administered for a time sufficient to induce an immune response against the tumor.
11. A method for treating a patient suffering from brain cancer, the method comprising co-administering to the patient at a peripheral, non-central nervous system site, granulocyte/macrophage colony stimulating factor with tumor antigen.

FIG. 1







FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/10540

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/19 A61K39/08

According to International Patent Classification (IPC) or to both national classification and IPC:

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 06867 A (WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH ET AL.) 15 April 1993 see page 6, line 6 - line 10 see page 7, line 20 - line 33 see claims 2,7,8,10; example 11 ---	1-11
X	WO 94 16716 A (VIROGENETICS CORPORATION) 4 August 1994 see abstract; claims 1,17 -----	1-11

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

22 September 1997

07.10.97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Alvarez Alvarez, C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/10540

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 1 - 11 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Application No

PCT/US 97/10540

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9306867 A	15-04-93	AU 677165 B AU 2777692 A CA 2120503 A EP 0607309 A JP 7502987 T US 5637483 A	17-04-97 03-05-93 15-04-93 27-07-94 30-03-95 10-06-97
WO 9416716 A	04-08-94	AU 6165294 A CA 2153336 A EP 0680331 A JP 9503902 T	15-08-94 04-08-94 08-11-95 22-04-97

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.